ClinicalTrials.gg
CompletedNCT00548171Updated Jan 13, 2020Results posted

Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058

A Phase 4 interventional study of Boostrix™ in Acellular Pertussis, Tetanus and Diphtheria, sponsored by GlaxoSmithKline. Completed at 1 site in Australia. Open to participants aged 28 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-13.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
203
Allocation
Non-randomized
Ages
28 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing boostrix in Tetanus — 2 open to participants now, 2 under way, none of them phase 3. Boostrix · Tetanus.

Enrollment
17th of 22
203 · median 554
Started
2007
with 3 others
Phase 4
8 of 22
none open now
Registered
9th of 22
by date
Lead sponsor
18 of 22
GlaxoSmithKline

Among the 22 studies testing boostrix in Tetanus, this one is the 17th largest by enrollment, is one of 4 that started in 2007, is one of 8 in phase 4, and was the 9th registered.

Tetanus

318 studies on the registry are indexed under Tetanus; 29 are open to participants now.

Browse Tetanus studies →

Open to participants now

2 of the 22 studies testing boostrix in Tetanus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About boostrix

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 16 Tetanus studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 28 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing boostrix in Tetanus, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of repeating dTpa booster in adults 10 years after previous booster vaccination with dTpa in a previous clinical study (NCT01267058). Only subjects who received the booster vaccination in a previous clinical study are eligible for participation in this study. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

No new recruitment will be performed in this booster phase (see inclusion criteria).

03

Conditions studied

  • Acellular Pertussis
  • Tetanus
  • Diphtheria
  • Diphtheria-Tetanus-acellular Pertussis Vaccines

Browse trials for

04

Who can participate

Ages eligible
28 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
  • Subjects who have received dTpa vaccine or Td and pa vaccines in study 263855/002 .
  • A male or female subject, recruited 10 years (+/- 9 months) after booster vaccination in study 263855/002.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • If the subject is female, she must be of non- or, if of childbearing potential, she must be abstinent or have used adequate precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of booster vaccination.
  • Written obtained from the subject.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of or other immune-modifying drugs within six months prior to the booster dose.
  • Administration of a vaccine not foreseen by the study protocol within 30 days prior to booster vaccination, or planned administration during the active study period
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product
  • Previous booster vaccination against diphtheria, tetanus or pertussis since the last dose received in study 263855/002
  • History of diphtheria, tetanus, or pertussis diseases.
  • Any confirmed or suspected immunosuppressive or immunodeficiency condition, based on medical history and physical examination
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period.
  • Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.
  • Occurrence of any of the following adverse event after a previous administration of a DTP vaccine :- reaction to any component of the vaccine; - encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine; - fever ≥ 40 °C (axillary temperature) within 48 hours of vaccination not due to another identifiable cause; - collapse or shock-like state within 48 hours of vaccination; - convulsions with or without fever, occurring within 3 days of vaccination.
  • Acute disease at the time of enrolment.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
203 participants (actual)

Study arms

  • Experimental
    Boostrix I Group

    Subjects who had received the Boostrix™ vaccine in the primary study 263855/002 (NCT01267058), were boosted in the current study with one dose of the same vaccine, intramuscularly in the deltoid region of the non-dominant arm.

    Biological: Boostrix™

  • Active comparator
    Boostrix II Group

    Subjects who had received the Td vaccines in the primary study 263855/002 (NCT01267058), were boosted in the current study with one dose of the Boostrix™ vaccine intramuscularly in the deltoid region of the non-dominant arm.

    Biological: Boostrix™

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations Equal to or Above (≥) 0.1 International Units Per Milliliter (IU/mL)

    Cut-off values defining seroprotected subjects against anti-DT/anti-TT were greater than or equal to (≥) 0.1 IU/mL as assessed by the Enzyme-Linked Immunosorbent Assay (ELISA). The analysis was performed and presents results only for subjects who in the previous study NCT01267058, had received the Boostrix™ vaccine as first booster.

    Time frame: One month after the booster vaccination [PI(M1)]

Secondary outcomes

  1. Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations Equal to or Above Cut-off Values

    Cut-off values, as assessed by ELISA, were greater than or equal to (≥) 0.1 IU/mL and (≥) 1 IU/mL.

    Time frame: Prior to (PRE) and one month after [PI(M1)] the booster vaccination

  2. Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations

    Concentrations were presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).

    Time frame: Prior to (PRE) and one month after [PI(M1)] the booster vaccination

  3. Number of Subjects With Anti-DT and Anti-TT Antibody Concentrations Equal to or Above Cut-off Values

    Cut-off values, as assessed by ELISA, were greater than or equal to (≥) 0.1 IU/mL and ≥ 1 IU/mL. This endpoint presents results for subjects included in the ATP cohort for antibody persistence.

    Time frame: Prior (PRE) to booster vaccination

  4. Anti-DT and Anti-TT Antibody Concentrations

    Concentrations are presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).

    Time frame: Prior to the booster vaccination

  5. Number of Seronegative Subjects for Anti-DT Antibodies - ELISA

    Seronegative subjects were defined as subjects with anti-DT antibody concentrations \< 0.1 IU/mL prior to vaccination, as assessed by ELISA.

    Time frame: Prior the booster vaccination

  6. Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test

    Sera with ELISA concentrations \<0.1 IU/mL before vaccination were tested for neutralising antibodies using a Vero-cell neutralisation assay. Concentrations ≥0.016 IU/mL by Vero-cell indicated detectable anti-diphteria neutralising antibodies.

    Time frame: Prior the booster vaccination

  7. Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies

    Cut-off values, as assessed by ELISA, were greater than or equal to ≥ 5 ELISA Units per millilitre (EL.U/mL) defining seropositive subjects post-vaccination.

    Time frame: Prior the booster vaccination

  8. Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

    Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EL.U/mL)

    Time frame: Prior the booster vaccination

  9. Number of Seronegative Subjects for Anti-DT Antibodies - ELISA.

    Seronegative subjects were defined as subjects with anti-DT antibody concentrations \< 0.1 IU/mL prior to vaccination, as assessed by ELISA.

    Time frame: Prior to the booster vaccination

  10. Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test.

    Sera with ELISA concentrations \<0.1 IU/mL before vaccination were tested for neutralising antibodies using a Vero-cell neutralisation assay. Concentrations ≥0.016 IU/mL by Vero-cell indicated detectable anti-diphteria neutralising antibodies.

    Time frame: Prior to the booster vaccination

  11. Number of Seronegative Subjects for Anti-DT Antibodies - ELISA

    Seronegative subjects were defined as subjects with anti-DT antibody concentrations \< 0.1 IU/mL prior to vaccination, as assessed by ELISA.

    Time frame: One month after the booster vaccination

  12. Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test

    Sera with ELISA concentrations \<0.1 IU/mL before vaccination were tested for neutralising antibodies using a Vero-cell neutralisation assay. Concentrations ≥ 0.016 IU/mL by Vero-cell indicated detectable anti-diphteria neutralising antibodies.

    Time frame: One month after the booster vaccination

  13. Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN Antibodies

    Cut-off values, as assessed by ELISA, were greater than or equal to ≥ 5 ELISA Units per millilitre (EL.U/mL) defining seropositive subjects post-vaccination.

    Time frame: Prior to (PRE) and one month after [PI(M1)] the booster vaccination

  14. Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

    Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EL.U/mL).

    Time frame: Prior to (PRE) and one month after [PI(M1)] the booster vaccination

  15. Number of Subjects With Booster Response to Anti-PT, Anti-FHA and Anti-PRN

    Booster response was defined as appearance of antibodies in subjects who were seronegative at the pre-vaccination time point (i.e. with concentrations \< 5 El.U/mL) or at least 2-fold increase of pre-vaccination antibody concentrations in subjects who were seropositive at the pre-vaccination time point (i.e. with concentrations ≥5 El.U/mL).

    Time frame: One month after the booster vaccination

  16. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Relationship analysis was not performed. For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.

    Time frame: During the 4-day (Day 0-3) follow-up period after booster vaccination

  17. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], headache, gastrointestinal symptoms \[nausea, vomiting, diarrhoea and/or abdominal pain\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.

    Time frame: During the 4-day (Day 0-3) follow-up period after booster vaccination

  18. Number of Subjects With Any Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.

    Time frame: During the 31-day (Day 0-30) follow-up period after booster vaccination

  19. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.

    Time frame: Following the booster vaccination

07

Results

Posted Jan 15, 2019

Participant flow

Participant flow — Overall Study
MilestoneBoostrix I GroupBoostrix II Group
Started16439
Completed16439
Not completed00

Outcome measures

PrimaryNumber of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations Equal to or Above (≥) 0.1 International Units Per Milliliter (IU/mL)

Cut-off values defining seroprotected subjects against anti-DT/anti-TT were greater than or equal to (≥) 0.1 IU/mL as assessed by the Enzyme-Linked Immunosorbent Assay (ELISA). The analysis was performed and presents results only for subjects who in the previous study NCT01267058, had received the Boostrix™ vaccine as first booster.

Time frame:
One month after the booster vaccination [PI(M1)]
Reported as:
Count of participants · Participants
Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoid (Anti-TT) Antibody Concentrations Equal to or Above (≥) 0.1 International Units Per Milliliter (IU/mL)
ParticipantsBoostrix I GroupBoostrix II Group
Anti-DT ≥ 0.1 PI(M1)15135
Anti-TT ≥ 0.1 PI(M1)15335
SecondaryNumber of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations Equal to or Above Cut-off Values

Cut-off values, as assessed by ELISA, were greater than or equal to (≥) 0.1 IU/mL and (≥) 1 IU/mL.

Time frame:
Prior to (PRE) and one month after [PI(M1)] the booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations Equal to or Above Cut-off Values
ParticipantsBoostrix I GroupBoostrix II Group
Anti-DT ≥ 0.1 IU/mL, PRE9520
Anti-DT ≥ 0.1 IU/mL, PI(M1)15135
Anti-DT ≥ 1 IU/mL, PRE247
Anti-DT ≥ 1 IU/mL, PI(M1)10623
Anti-TT ≥ 0.1 IU/mL, PRE14530
Anti-TT ≥ 0.1 IU/mL, PI(M1)15335
Anti-TT ≥ 1 IU/mL, PRE9023
Anti-TT ≥ 1 IU/mL, PI(M1)15335
SecondaryAnti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations

Concentrations were presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).

Time frame:
Prior to (PRE) and one month after [PI(M1)] the booster vaccination
Reported as:
Geometric mean · IU/mL
Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations
IU/mLBoostrix I GroupBoostrix II Group
Anti-DT, PRE0.200 (0.161 to 0.249)0.233 (0.138 to 0.392)
Anti-DT, PI(M1)1.889 (1.547 to 2.306)1.605 (1.111 to 2.319)
Anti-TT, PRE1.026 (0.859 to 1.224)0.845 (0.538 to 1.327)
Anti-TT, PI(M1)6.927 (6.204 to 7.735)5.933 (4.768 to 7.384)
SecondaryNumber of Subjects With Anti-DT and Anti-TT Antibody Concentrations Equal to or Above Cut-off Values

Cut-off values, as assessed by ELISA, were greater than or equal to (≥) 0.1 IU/mL and ≥ 1 IU/mL. This endpoint presents results for subjects included in the ATP cohort for antibody persistence.

Time frame:
Prior (PRE) to booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Anti-DT and Anti-TT Antibody Concentrations Equal to or Above Cut-off Values
ParticipantsBoostrix I GroupBoostrix II Group
Anti-DT ≥ 0.1 IU/mL, PRE10222
Anti-DT ≥ 1 IU/mL, PRE257
Anti-TT ≥ 0.1 IU/mL, PRE15232
Anti-TT ≥ 1 IU/mL, PRE9525
SecondaryAnti-DT and Anti-TT Antibody Concentrations

Concentrations are presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).

Time frame:
Prior to the booster vaccination
Reported as:
Geometric mean · IU/mL
Anti-DT and Anti-TT Antibody Concentrations
IU/mLBoostrix I GroupBoostrix II Group
Anti-DT, PRE0.208 (0.168 to 0.257)0.235 (0.144 to 0.384)
Anti-TT, PRE1.031 (0.868 to 1.225)0.898 (0.581 to 1.386)
SecondaryNumber of Seronegative Subjects for Anti-DT Antibodies - ELISA

Seronegative subjects were defined as subjects with anti-DT antibody concentrations \< 0.1 IU/mL prior to vaccination, as assessed by ELISA.

Time frame:
Prior the booster vaccination
Reported as:
Count of participants · Participants
Number of Seronegative Subjects for Anti-DT Antibodies - ELISA
ParticipantsBoostrix I GroupBoostrix II Group
Number of Seronegative Subjects for Anti-DT Antibodies - ELISA5614
SecondaryNumber of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test

Sera with ELISA concentrations \<0.1 IU/mL before vaccination were tested for neutralising antibodies using a Vero-cell neutralisation assay. Concentrations ≥0.016 IU/mL by Vero-cell indicated detectable anti-diphteria neutralising antibodies.

Time frame:
Prior the booster vaccination
Reported as:
Count of participants · Participants
Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test
ParticipantsBoostrix I GroupBoostrix II Group
Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test164
SecondaryNumber of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies

Cut-off values, as assessed by ELISA, were greater than or equal to ≥ 5 ELISA Units per millilitre (EL.U/mL) defining seropositive subjects post-vaccination.

Time frame:
Prior the booster vaccination
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Haemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies
ParticipantsBoostrix I GroupBoostrix II Group
Anti-PT13723
Anti-FHA15937
Anti-PRN15133
SecondaryAnti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EL.U/mL)

Time frame:
Prior the booster vaccination
Reported as:
Geometric mean · EL.U/mL
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
EL.U/mLBoostrix I GroupBoostrix II Group
Anti-PT13.9 (11.9 to 16.2)8.3 (5.9 to 11.7)
Anti-FHA137.2 (116.7 to 161.3)115.6 (80.2 to 166.5)
Anti-PRN56.6 (44.2 to 72.4)50.2 (27.9 to 90.4)
SecondaryNumber of Seronegative Subjects for Anti-DT Antibodies - ELISA.

Seronegative subjects were defined as subjects with anti-DT antibody concentrations \< 0.1 IU/mL prior to vaccination, as assessed by ELISA.

Time frame:
Prior to the booster vaccination
Reported as:
Count of participants · Participants
Number of Seronegative Subjects for Anti-DT Antibodies - ELISA.
ParticipantsBoostrix I GroupBoostrix II Group
Number of Seronegative Subjects for Anti-DT Antibodies - ELISA.5614
SecondaryNumber of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test.

Sera with ELISA concentrations \<0.1 IU/mL before vaccination were tested for neutralising antibodies using a Vero-cell neutralisation assay. Concentrations ≥0.016 IU/mL by Vero-cell indicated detectable anti-diphteria neutralising antibodies.

Time frame:
Prior to the booster vaccination
Reported as:
Count of participants · Participants
Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test.
ParticipantsBoostrix I GroupBoostrix II Group
Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test.164
SecondaryNumber of Seronegative Subjects for Anti-DT Antibodies - ELISA

Seronegative subjects were defined as subjects with anti-DT antibody concentrations \< 0.1 IU/mL prior to vaccination, as assessed by ELISA.

Time frame:
One month after the booster vaccination
Reported as:
Count of participants · Participants
Number of Seronegative Subjects for Anti-DT Antibodies - ELISA
ParticipantsBoostrix I GroupBoostrix II Group
Number of Seronegative Subjects for Anti-DT Antibodies - ELISA10
SecondaryNumber of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test

Sera with ELISA concentrations \<0.1 IU/mL before vaccination were tested for neutralising antibodies using a Vero-cell neutralisation assay. Concentrations ≥ 0.016 IU/mL by Vero-cell indicated detectable anti-diphteria neutralising antibodies.

Time frame:
One month after the booster vaccination
Reported as:
Count of participants · Participants
Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test
ParticipantsBoostrix I GroupBoostrix II Group
Number of Seronegative Subjects for Anti-DT Antibodies - Neutralisation Test0—
SecondaryNumber of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN Antibodies

Cut-off values, as assessed by ELISA, were greater than or equal to ≥ 5 ELISA Units per millilitre (EL.U/mL) defining seropositive subjects post-vaccination.

Time frame:
Prior to (PRE) and one month after [PI(M1)] the booster vaccination
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN Antibodies
ParticipantsBoostrix I GroupBoostrix II Group
Anti-PT, PRE13122
Anti-PT, PI(M1)15235
Anti-FHA, PRE15235
Anti-FHA, PI(M1)15235
Anti-PRN, PRE14431
Anti-PRN, PI(M1)15334
SecondaryAnti-PT, Anti-FHA and Anti-PRN Antibody Concentrations

Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per millilitre (EL.U/mL).

Time frame:
Prior to (PRE) and one month after [PI(M1)] the booster vaccination
Reported as:
Geometric mean · EL.U/mL
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
EL.U/mLBoostrix I GroupBoostrix II Group
Anti-PT, PRE13.9 (11.9 to 16.2)8.4 (5.9 to 11.8)
Anti-PT, PI(M1)126.5 (109.9 to 145.6)120.8 (88.9 to 164.2)
Anti-FHA, PRE140.2 (118.9 to 165.4)119.3 (81.3 to 175.1)
Anti-FHA, PI(M1)615.3 (543.8 to 696.2)677.4 (513.7 to 893.2)
Anti-PRN, PRE56.2 (43.6 to 72.5)45.7 (24.9 to 83.7)
Anti-PRN, PI(M1)303.6 (259.6 to 355.0)370.7 (280.5 to 489.9)
SecondaryNumber of Subjects With Booster Response to Anti-PT, Anti-FHA and Anti-PRN

Booster response was defined as appearance of antibodies in subjects who were seronegative at the pre-vaccination time point (i.e. with concentrations \< 5 El.U/mL) or at least 2-fold increase of pre-vaccination antibody concentrations in subjects who were seropositive at the pre-vaccination time point (i.e. with concentrations ≥5 El.U/mL).

Time frame:
One month after the booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Booster Response to Anti-PT, Anti-FHA and Anti-PRN
ParticipantsBoostrix I GroupBoostrix II Group
Anti-PT14833
Anti-FHA11931
Anti-PRN10626
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site. Relationship analysis was not performed. For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.

Time frame:
During the 4-day (Day 0-3) follow-up period after booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
ParticipantsBoostrix Pooled Group
Any Pain142
Grade 3 Pain2
Any Redness72
Grade 3 Redness14
Any Swelling66
Grade 3 Swelling20
SecondaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were fatigue, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], headache, gastrointestinal symptoms \[nausea, vomiting, diarrhoea and/or abdominal pain\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination. For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.

Time frame:
During the 4-day (Day 0-3) follow-up period after booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
ParticipantsBoostrix Pooled Group
Any Fatigue47
Grade 3 Fatigue0
Related Fatigue25
Any Fever6
Grade 3 Fever0
Related Fever5
Any Gastrointestinal symptom15
Grade 3 Gastrointestinal symptom1
Related Gastrointestinal symptom7
Any Headache39
Grade 3 Headache2
Related Headache18
SecondaryNumber of Subjects With Any Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.

Time frame:
During the 31-day (Day 0-30) follow-up period after booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any Unsolicited Adverse Events (AEs)
ParticipantsBoostrix Pooled Group
Number of Subjects With Any Unsolicited Adverse Events (AEs)35
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. For safety assessment Boostrix I Group and Boostrix II Group were pooled into Booster Pooled Group.

Time frame:
Following the booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsBoostrix Pooled Group
Number of Subjects With Serious Adverse Events (SAEs)0

Adverse events

Collected over Solicited symptoms: during the 4-day (Days 0-3) follow-up period post booster vaccination; Unsolicited AEs: during the 31-day (Days 0-30) follow-up period post booster vaccination; SAEs: during the entire study period (following booster vaccination).. Non-serious events are listed at a 2.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Boostrix Pooled Group0/203 (0%)0/203 (0%)163/203 (80.3%)
Most frequent other events
Most frequent other events
EventBoostrix Pooled Group
PainGeneral disorders142/203
ErythemaSkin and subcutaneous tissue disorders72/203
SwellingGeneral disorders66/203
FatigueGeneral disorders47/203
HeadacheNervous system disorders40/203
Gastrointestinal disorderGastrointestinal disorders15/203
Injection site pruritusGeneral disorders9/203
PyrexiaGeneral disorders6/203

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Boostrix I GroupBoostrix II GroupTotal
Mean50.1 ± 9.9851.0 ± 8.7050.27 ± 9.73
Sex: Female, Male
Sex: Female, Male(Participants)Boostrix I GroupBoostrix II GroupTotal
Female10733140
Male57663
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Boostrix I GroupBoostrix II GroupTotal
Count of participants——0
08

Study locations

1 site
  • GSK Investigational Site
    Westmead, New South Wales 2145, Australia
09

References and documents

Publications

  • Booy R, Van der Meeren O, Ng SP, Celzo F, Ramakrishnan G, Jacquet JM. A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix) is immunogenic and well tolerated in adults. Vaccine. 2010 Dec 10;29(1):45-50. doi: 10.1016/j.vaccine.2010.10.025. Epub 2010 Oct 23. PubMed 20974302 ↗
  • Booy R et al. The decennial administration of a reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (dTpa; BoostrixTM) in adults. Abstract presented at IDSA. Philadelphia, USA, 29 October- 1 November 2009.
  • Mertsola J et al. The immunogenicity of repeated administration of reduced-antigen-content dTpa booster in adults. Abstract presented at WSPID. Buenos Aires, Argentina, 19-22 November 2009.
  • Mertsola J et al. The safety of repeated administration of Boostrix™, a reduced-antigen-content dTpa booster. Abstract presented at Excellence In Paediatrics (EIP). Florence, Italy, 3-6 December 2009.
  • Mertsola J et al. The safety of repeated administration of reduced-antigen-content dTpa boosters. Abstract presented at WSPID. Buenos Aires, Argentina, 19-22 November 2009.

Individual participant data

Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2007 to primary completion in Apr 2008, 5 months.

Results were first posted in Jan 2019, 10 years 8 months after primary completion. A results delay was requested in Sep 2009.

Of 19 phase 4 interventional studies under Tetanus, half reached primary completion within 22 months of starting (the median); a quarter within 6 and three quarters within 30. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2007
First posted
Oct 23, 2007
StartActual
Nov 5, 2007
Primary completionActual
Apr 30, 2008
CompletionActual
Apr 30, 2008
Results delay requested
Sep 9, 2009
Results first posted
Jan 15, 2019
Last update
Jan 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00548171
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 23, 2007
Start date
Nov 5, 2007
Primary completion
Apr 30, 2008
Completion
Apr 30, 2008
Results posted
Jan 15, 2019
Last update
Jan 13, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Boostrix

Start the discussion